The agreement will focus on developing safe,
effective, all-natural products for the emerging psychedelic
industry
VANCOUVER, BC, Jan. 6, 2021 /CNW/ - Numinus Wellness
Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company
creating an ecosystem of health solutions centered around
developing and supporting the safe, evidence-based, accessible use
of psychedelic-assisted psychotherapies (PAP), announced today that
it has signed a lab services agreement with Optimi Health Corp.
("Optimi"), developers of a vertically integrated functional
mushroom brand focused on the health and wellness sector, to
further the research and development of Canadian-grown
psilocybin-producing mushrooms.
Through this first-of-its-kind agreement, Optimi will utilize
and leverage Numinus Bioscience's laboratories, equipment, services
and expertise, with the goal of developing products for the
emerging psychedelic industry. Optimi has applied to Health Canada
for a research exemption allowing it to conduct activities
involving psychedelic compounds and, in advance of approval, will
undertake a number of research and development projects with
Numinus related to Psilocybe mushrooms, psychedelic
compounds, and formulations.
"We're excited to partner with Optimi and its highly experienced
and passionate team to advance psychedelic initiatives and develop
safe and effective products," said Payton
Nyquvest, CEO, Founder and Chairman, Numinus. "Demand for
natural products that optimize mental health and performance
continues to grow, and we see great potential in
psilocybin-producing mushroom products to provide these benefits.
We look forward to working with Optimi to advance development in
this rapidly expanding marketplace."
"Numinus is an ideal partner to further our research and
development of Psilocybe mushroom and associated
derivatives-based products," said Mike
Stier, CEO, Optimi Health Corp. "Numinus' state-of-the art
laboratory, specialized equipment and second-to-none expertise in
psychedelic research will be critical to developing the safe,
effective, all-natural products that we believe to be the flagship
products in this space."
Under the terms of the agreement, Optimi will pay an initial
retainer with fees for services determined and replenished on a
project-by-project basis. Each project is expected to be a
stand-alone project that is defined by a Statement of Work, and
while certain projects may build upon previously completed ones,
there may also be several projects undertaken at the same time.
Optimi will further issue to Numinus 150,000 fully paid and
non-assessable common shares in the capital of Optimi (each a
"Share") on January 4, 2021 and
150,000 Shares upon completing the first project that the parties
enter into. All shares will be subject to resale restrictions
expiring four months and one day from their date of issue.
Numinus Bioscience's laboratory provides services including
cultivation, analytical testing, product research and development,
and ancillary services in the area of psychedelics. The agreement
with Optimi is effective January 4,
2021 and constitutes one of the first opportunities for
Numinus to generate revenue from independent parties utilizing its
state of the art laboratory facility, scientific expertise, and
authorization to work with controlled drugs and substances.
About Numinus
Numinus Wellness Inc. (TSXV: NUMI) is a mental
health and wellness company creating an ecosystem of solutions
centred around safe, evidence-based, accessible
psychedelic-assisted psychotherapy to help people heal and be
well.
Numinus Health is dedicated to delivering innovative
treatments to address physical, mental, and emotional health,
through clinics and virtual services.
Numinus R&D is conducting implementation science
and leveraging partnerships to beta-test and refine optimal models
of psychedelic-assisted psychotherapy delivery, setting the stage
for approved routine use in mental health and wellness care.
Numinus Bioscience is focused on developing testing
methods and effective formulas for the evolving psychedelics space.
Health Canada licences, scientific
expertise, and new technologies facilitate ongoing innovation, and
high-throughput contract services generate established revenue.
Learn more at numinus.ca, and follow us on Facebook, Twitter,
and Instagram.
About Optimi Health
Optimi Health is developing a vertically integrated Canadian
functional mushroom brand that focuses on the health and wellness
sector. The Company intends to cultivate, extract, process and
distribute high quality strains of fungi products in its facility
located in Princeton, British
Columbia. Optimi intends to grow and process functional
mushrooms in order to develop and sell its mushrooms and related
health food products directly to consumers, and to other health
food brands and distributors.
Find out more at optimihealth.ca
Forward Looking Statements
This news release contains forward-looking statements within
the meaning of applicable securities laws. All statements that are
not historical facts, including without limitation, statements
regarding future estimates, plans, programs, forecasts,
projections, objectives, assumptions, expectations or beliefs of
future performance, are "forward-looking statements."
Forward-looking statements can be identified by the use of words
such as "plans", "expects" or "does not expect", "is expected",
"estimates", "intends", "anticipates" or "does not anticipate", or
"believes", or variations of such words and phrases or statements
that certain actions, events or results "may", "could", "would",
"might" or "will" be taken, occur or be achieved. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward looking statements. Such risks and uncertainties include,
among others, dependence on obtaining and maintaining regulatory
approvals, including acquiring and renewing federal, provincial,
municipal, local or other licences and any inability to obtain all
necessary governmental approvals licences and permits to operate
and expand the Company's facilities; regulatory or political change
such as changes in applicable laws and regulations, including
federal and provincial legalization, due to inconsistent public
opinion, perception of the medical-use and adult-use marijuana
industry, bureaucratic delays or inefficiencies or any other
reasons; any other factors or developments which may hinder market
growth; the Company's limited operating history and lack of
historical profits; reliance on management; the Company's
requirements for additional financing, and the effect of capital
market conditions and other factors on capital availability;
competition, including from more established or better financed
competitors; and the need to secure and maintain corporate
alliances and partnerships, including with research and development
institutions, customers and suppliers. These factors should be
considered carefully, and readers are cautioned not to place undue
reliance on such forward-looking statements. Although the Company
has attempted to identify important risk factors that could cause
actual actions, events or results to differ materially from those
described in forward-looking statements, there may be other risk
factors that cause actions, events or results to differ from those
anticipated, estimated or intended. There can be no assurance that
forward-looking statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in forward-looking statements. The Company has no
obligation to update any forward-looking statement, even if new
information becomes available as a result of future events, new
information or for any other reason except as required by
law.
SOURCE Numinus Wellness Inc.